Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natrecor in acutely decompensated congestive heart failure (PROACTION)
NCT00270387Phase 3Completed
- Sponsor
- Scios Inc.
- Start
- Jan 2001
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Natrecor + Standard Therapy with Placebo + Standard Therapy (2 arms). Primary endpoints: Safety of Natrecor administration, Number of hospital readmissions at 30 days and 1 more. Started Jan 2001; status: completed.
02
Drugs
nesiritide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00270387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270387.